NVO vs. LLY, JNJ, MRK, ABBV, AZN, NVS, ABT, PFE, UNH, and TMO
Should you be buying Novo Nordisk A/S stock or one of its competitors? The main competitors of Novo Nordisk A/S include Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), AbbVie (ABBV), AstraZeneca (AZN), Novartis (NVS), Abbott Laboratories (ABT), Pfizer (PFE), UnitedHealth Group (UNH), and Thermo Fisher Scientific (TMO). These companies are all part of the "medical" sector.
Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.
Eli Lilly and Company presently has a consensus price target of $769.53, suggesting a potential downside of 0.06%. Novo Nordisk A/S has a consensus price target of $133.60, suggesting a potential upside of 1.30%. Given Eli Lilly and Company's higher probable upside, analysts clearly believe Novo Nordisk A/S is more favorable than Eli Lilly and Company.
Eli Lilly and Company pays an annual dividend of $5.20 per share and has a dividend yield of 0.7%. Novo Nordisk A/S pays an annual dividend of $1.33 per share and has a dividend yield of 1.0%. Eli Lilly and Company pays out 76.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novo Nordisk A/S pays out 45.9% of its earnings in the form of a dividend. Eli Lilly and Company has raised its dividend for 10 consecutive years and Novo Nordisk A/S has raised its dividend for 1 consecutive years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.
In the previous week, Eli Lilly and Company had 9 more articles in the media than Novo Nordisk A/S. MarketBeat recorded 48 mentions for Eli Lilly and Company and 39 mentions for Novo Nordisk A/S. Eli Lilly and Company's average media sentiment score of 0.60 beat Novo Nordisk A/S's score of 0.51 indicating that Novo Nordisk A/S is being referred to more favorably in the news media.
82.5% of Eli Lilly and Company shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 0.1% of Eli Lilly and Company shares are owned by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Novo Nordisk A/S has lower revenue, but higher earnings than Eli Lilly and Company. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.
Novo Nordisk A/S has a net margin of 36.56% compared to Novo Nordisk A/S's net margin of 17.08%. Eli Lilly and Company's return on equity of 91.70% beat Novo Nordisk A/S's return on equity.
Eli Lilly and Company has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500.
Eli Lilly and Company received 770 more outperform votes than Novo Nordisk A/S when rated by MarketBeat users. Likewise, 70.07% of users gave Eli Lilly and Company an outperform vote while only 60.60% of users gave Novo Nordisk A/S an outperform vote.
Summary
Eli Lilly and Company beats Novo Nordisk A/S on 12 of the 21 factors compared between the two stocks.
Get Novo Nordisk A/S News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Novo Nordisk A/S Competitors List
Related Companies and Tools
